JNK signaling maintains the mesenchymal properties of multi-drug resistant human epidermoid carcinoma KB cells through snail and twist1

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Zhan, Xia ^a   Feng, Xiaobing ^a,c,d   Kong, Ying ^a   Chen, Yi ^b   Tan, Wenfu ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c NANTONG UNIVERSITY   (China)

^d PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

C Jun N terminal kinases; Epithelial mesenchymal transition; Snail; Twist1

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN 1; NERVE CELL ADHESION MOLECULE; PROTEIN C JUN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; STAT5A PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR FOXO2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TATA; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; VINCRISTINE;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRAIN KB; CONTROLLED STUDY; EPITHELIUM CELL; GENE SILENCING; HUMAN; HUMAN CELL; MESENCHYME CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; GENES, JUN; HUMANS; KB CELLS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; NUCLEAR PROTEINS; PHENOTYPE; TRANSCRIPTION FACTORS; TWIST TRANSCRIPTION FACTOR; VIMENTIN; VINCRISTINE;

EID: 84875687877     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-180     Document Type: Article

References (39)

1. Redmond KM, Wilson TR, Johnston PG, Longley DB. Resistance mechanisms to cancer chemotherapy. Front Biosci 2008, 13:5138-5154.
2. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008, 65(20):3145-3167. 10.1007/s00018-008-8111-5, 18581055.
3. Yamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M, Hoffman RM. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res 2008, 68(2):516-520. 10.1158/0008-5472.CAN-07-3063, 18199547.
4. De Larco JE, Wuertz BR, Manivel JC, Furcht LT. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 2001, 61(7):2857-2861.
5. Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L, Liu BB, Li QS, Zhang W, Zhu XD, Liu L. Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin. BMC Cancer 2010, 10:219. 10.1186/1471-2407-10-219, 2880993, 20487542.
6. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006, 127(4):679-695. 10.1016/j.cell.2006.11.001, 17110329.
7. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008, 14(6):818-829. 10.1016/j.devcel.2008.05.009, 18539112.
8. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119(6):1420-1428. 10.1172/JCI39104, 2689101, 19487818.
9. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009, 119(6):1429-1437. 10.1172/JCI36183, 2689132, 19487819.
10. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7(2):131-142. 10.1038/nrm1835, 16493418.
11. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009, 9(8):537-549. 10.1038/nrc2694, 19629069.
12. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103(2):239-252. 10.1016/S0092-8674(00)00116-1, 11057897.
13. Hayakawa J, Depatie C, Ohmichi M, Mercola D. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem 2003, 278(23):20582-20592. 10.1074/jbc.M210992200, 12663670.
14. Sui H, Zhou S, Wang Y, Liu X, Zhou L, Yin P, Fan Z, Li Q. COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis 2011, 32(5):667-675. 10.1093/carcin/bgr016, 21296766.
15. Zhang XH, Zhang FY, Ji XJ, Li ZY. Vincristine-resistant human KB cell line and mechanism of multidrug resistance. Yao Xue Xue Bao 1994, 29(4):246-251.
16. Tan W, Martin D, Gutkind JS. The Galpha13-Rho signaling axis is required for SDF-1-induced migration through CXCR4. J Biol Chem 2006, 281(51):39542-39549. 10.1074/jbc.M609062200, 17056591.
17. Li MH, Miao ZH, Tan WF, Yue JM, Zhang C, Lin LP, Zhang XW, Ding J. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clin Cancer Res 2004, 10(24):8266-8274. 10.1158/1078-0432.CCR-04-0951, 15623602.
18. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001, 98(24):13681-13686. 10.1073/pnas.251194298, 61101, 11717429.
19. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890. 10.1016/j.cell.2009.11.007, 19945376.
20. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP, Xu ZD. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 2009, 15(8):2657-2665. 10.1158/1078-0432.CCR-08-2372, 19336515.
21. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009, 69(6):2400-2407. 10.1158/0008-5472.CAN-08-4312, 2657919, 19276344.
22. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009, 106(33):13820-13825. 10.1073/pnas.0905718106, 2720409, 19666588.
23. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S. c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 2005, 106(4):1382-1391. 10.1182/blood-2004-10-3819, 1895189, 15890690.
24. Das M, Garlick DS, Greiner DL, Davis RJ. The role of JNK in the development of hepatocellular carcinoma. Genes Dev 2011, 25(6):634-645. 10.1101/gad.1989311, 3059836, 21406557.
25. Sancho R, Nateri AS, de Vinuesa AG, Aguilera C, Nye E, Spencer-Dene B, Behrens A. JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J 2009, 28(13):1843-1854. 10.1038/emboj.2009.153, 2711188, 19521338.
26. Fujishita T, Aoki M, Taketo MM. JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in Apc(Delta716) mice. Gastroenterology 2011, 140(5):1556-1563. e1556, 10.1053/j.gastro.2011.02.007, 21320501.
27. Cheung LW, Leung PC, Wong AS. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 2006, 66(22):10902-10910. 10.1158/0008-5472.CAN-06-2217, 17108127.
28. McMurtry V, Simeone AM, Nieves-Alicea R, Tari AM. Leptin utilizes Jun N-terminal kinases to stimulate the invasion of MCF-7 breast cancer cells. Clin Exp Metastasis 2009, 26(3):197-204. 10.1007/s10585-008-9231-x, 19112600.
29. Fromigue O, Hamidouche Z, Marie PJ. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 2008, 283(45):30549-30556. 10.1074/jbc.M801436200, 2662148, 18757369.
30. Zhang Y, Rivera Rosado LA, Moon SY, Zhang B. Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling. J Biol Chem 2009, 284(19):12956-12965. 10.1074/jbc.M807845200, 2676027, 19269969.
31. Wang J, Kuiatse I, Lee AV, Pan J, Giuliano A, Cui X. Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation. Mol Cancer Res 2010, 8(2):266-277. 10.1158/1541-7786.MCR-09-0221, 2824784, 20145041.
32. Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty PB, Schwartz GK. Gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 2009, 69(2):573-582. 10.1158/0008-5472.CAN-08-2088, 3242515, 19147571.
33. Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, Aberson HL, Ferreira CV, Peppelenbosch MP, Spek CA. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 2010, 29(48):6314-6322. 10.1038/onc.2010.375, 20802532.
34. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, Vega F. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 2011, 30(49):4874-4886. 10.1038/onc.2011.195, 3165099, 21625222.
35. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
36. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29(34):4741-4751. 10.1038/onc.2010.215, 3176718, 20531305.
37. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5(4):275-284. 10.1038/nrc1590, 15803154.
38. Sui H, Fan ZZ, Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res 2012, 40(2):426-435.
39. Vasilevskaya I, O'Dwyer PJ. Role of Jun and Jun kinase in resistance of cancer cells to therapy. Drug Resist Updat 2003, 6(3):147-156. 10.1016/S1368-7646(03)00043-8, 12860462.